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ABSTRACT: Stimulus-responsive drug delivery nanosystems
(DDSs) are of great significance in improving cancer therapy
for intelligent control over drug release. However, among
them, many DDSs are unable to realize rapid and sufficient
drug release because most internal stimulants might be
consumed during the release process. To address the plight,
an abundant supply of stimulants is highly desirable. Herein, a
core crosslinked pullulan-di-(4,1-hydroxybenzylene)diselenide
nanosystem, which could generate abundant exogenous-
stimulant reactive oxygen species (ROS) via tumor-specific
NAD(P)H:quinone oxidoreductase-1 (NQO1) catalysis, was
constructed by the encapsulation of β-lapachone. The
enzyme-catalytic-generated ROS induced self-triggered cascade amplification release of loaded doxorubicin (DOX) in the
tumor cells, thus achieving efficient delivery of DOX to the nuclei of tumor cells by breaking the diselenide bond of the
nanosystem. As a result, the antitumor effect of this nanosystem was significantly improved in the HepG2 xenograft model. In
general, this study offers a new paradigm for utilizing the interaction between the loaded agent and carrier in the tumor cells to
obtain self-triggered drug release in the design of DDSs for enhanced cancer therapy.
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1. INTRODUCTION
Cancer therapy based on nanosystems has been considered as
potential alternatives to conventional chemotherapy because
they could alter the pharmacokinetics and biodistribution of
drugs and exert a stronger antitumor effect.1−4 However, drug
delivery nanosystems (DDSs) usually failed in realizing
sufficient drug release and delivery to the nuclei of tumor
cells, limiting their clinical significance.5 Currently, many
research studies focus on developing DDSs with stimulus-
responsive properties.6−8 Ye et al. reported pH-responsive
micelles for the co-delivery doxorubicin (DOX)/siRNA. The
nanosystem was stable in the neutral environment and could
release DOX/siRNA in the acidic environment.9 Wang et al.
constructed core−shell−SS−shell-structured magnetic compo-
site nanoparticles with a combination of PTT and DOX, which
was redox-responsive in the cytoplasm and released the loaded
DOX.10 Naz et al. developed enzyme-responsive mesoporous
silica nanoparticles for mitochondria multistage-targeted drug
delivery.11 Yet, many stimulus-responsive DDSs are unable to
achieve rapid and sufficient drug release as internal stimulants
(such as glutathione, H+, reactive oxygen species, enzymes,
etc., and their combinations12−14) are largely exhausted during
the release process.7,15−18 Therefore, introducing an abundant
supply of exogenous stimulants to trigger drug release in the
tumor cells is highly desirable.
It is reported that the NAD(P)H:quinone oxidoreductase-1
(NQO1) enzyme is overexpressed in different types of tumor
cells up to 100 times.19 β-Lapachone could generate reactive
oxygen species (ROS) through catalysis of the NQO1
enzyme.20,21 Ye et al. confirmed that β-lapachone could
increase the ROS level and further overcome multidrug
resistance in the tumor cells.21 During the catalysis process,
the NQO1 enzyme is not involved in the reaction and it could
not be consumed and thus continuously provide stimulants
during the drug release process. Therefore, using β-lapachone
to amplify the ROS stimulant level in the tumor cells, as well as
to overcome internal ROS heterogeneous distribution in the
tumor tissues, helps to increase the release and nuclear delivery
of the drug from ROS-responsive DDSs through cascade
amplification.
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To achieve efficient cancer therapy, successful delivery of
DDSs into the tumor is just as important as sufficient drug
release. Extensive studies suggested that DDSs constructed
with modified polysaccharides (e.g. pullulan, chitosan, and
hyaluronic acid) showed feasible stability in vivo, which
contributed to traversing the tumor vessel and accumulating in
the tumor tissue.22−24 Meanwhile, in others’ and our previous
work, pullulan polysaccharide nanocarriers exhibited favorable
stability, high drug loading capability, and hepatic targeting
efficacy.25−31
Herein, inspired by the effect of β-lapachone to generate
ROS, and based on the successful application of modified
pullulan polysaccharide DDSs as well as our previous research,
as shown in Figure 1, we developed a new core crosslinked
pullulan nanosystem containing diselenide bond, which was
ROS-responsive and encapsulated high loading content of β-
lapachone and DOX. The crosslinked nanoparticles could
prevent premature drug leakage during the delivery process,
thus improving drug stability in the nanosystem.32,33
Furthermore, we explored how the cross-linking influenced
the physical characteristics and the biological fate of this
nanosystem. After being endocytosed by tumor cells, the
nanosystem would first release a portion of β-lapachone in the
presence of internal stimulants (glutathione or ROS), which
could induce a significant increase of ROS via NQO1 catalysis.
The generated ROS, like a kindling, could subsequently self-
trigger the break of diselenide (Se−Se) bond and disintegrate
the nanosystem, leading to amplified β-lapachone/DOX
release like fireworks. More importantly, β-lapachone and
ROS could induce cellular apoptosis,34−36 and thus they have
been considered as significant therapeutic agents. We
integrated multiple mechanisms into a single nanosystem as
an exciting therapeutic candidate. Therefore, this design might
achieve enhanced cancer therapy through precise spatiotem-
poral control over drug release and efficient drug delivery to
the nuclei of tumor cells.
2. EXPERIMENTAL SECTION
2.1. Synthesis and Characterization of Pu-HBSe Conjugates.
100% hydrazine monohydrate (1 mL, 25 mmol) was added dropwise
into a mixture of sodium hydroxide (1.52 g, 38 mmol) and selenium
powder (1.98 g, 25 mmol) in anhydrous dimethylformamide (DMF,
100 mL) at room temperature; then the mixture was vigorously
stirred for 2 h. Afterward, 4-bromobenzyl (4.675 g, 25 mmol) was
immersed into the reaction mixture, stirred, and refluxed at 160 °C for
4 h. After cooling to room temperature, the reaction mixture was
diluted by water and extracted by ethyl acetate. The organic phase was
dried by Na2SO4, the solvent was removed by a rotary evaporator, and
the purified di-(4,1-hydroxybenzylene)diselenide (HBSe) were
obtained by drying in vacuo.37
Carboxymethyl pullulan (CMP) was synthesized according to our
previously reported methods.27 Subsequently, CMP and EDCI were
dissolved in deionized water and stirred for 30 min. Then, the
solution of HBSe in DMF was added dropwise into the above mixture
and stirred for 5 h. The reaction mixture was extracted with ethyl
acetate, and the aqueous phase was collected. The collected mixture
was dialyzed against deionized water for 24 h and lyophilized to
obtain Pu-HBSe conjugates. The composition was analyzed by 1H
NMR (AVANCE 500, Japan) and Fourier transform infrared
spectroscopy (FTIR, PerkinElmer 2000, UK).
The remaining experimental procedures could be found in the
Supporting Information.
3. RESULTS AND DISCUSSION
3.1. Preparation and Characterization. In this work, a
new ROS-responsive Pu-HBSe conjugate was synthesized for
the first time by graft modification of HBSe containing Se−Se
bond to the CMP backbone according to Figures 1 and S1.
The chemical structure of the Pu-HBSe conjugate was
determined by 1H NMR and FTIR by comparing the peaks
of CMP, HBSe, and Pu-HBSe. The Pu-HBSe 1H NMR
spectrum permitted the identification of the protons: 3.00−
4.00 ppm (4H, glucose C2, C3, C4, and C5), 4.60−5.40 ppm
(glucose, −OH), 4.82 ppm (1H, s, 1-glucose a-1,6), 5.03 ppm
(1H, s, 2-glucose a-1,4), 7.18 ppm (4H, d, a-H2), and 7.45
ppm (4H, d, b-H2). The 1H NMR results show the
characteristic peaks of HBSe at 7−8 ppm in the Pu-HBSe
spectrum (Figure S2a, Supporting Information), suggesting the
successful synthesis of the conjugate, which is further validated
by FTIR characterization (Figure S2b, Supporting Informa-
tion). The FTIR spectra show a clear carbonyl signal at 1704
cm−1 in the Pu-HBSe spectrum, indicating to the successful
binding of CMP to HBSe.
The Pu-HBSe conjugate with amphiphilicity self-assembled
to form nanoparticles in water. A series of β-lapachone/DOX-
NCS with different ratios of β-lapachone/DOX were prepared
by adjusting the feed ratio of β-lapachone/DOX to nano-
carriers (Table S1, Supporting Information). To strengthen the
nanosystem stability and minimize the drug leakage during
circulation, after loading β-lapachone/DOX, facile visible light
(incandescent light bulb, 25 W, 184 Lux)-induced diselenide
metathesis and regeneration38 was employed to crosslink
nanocarriers for 3 h to fabricate the core crosslinked
nanosystem (β-lapachone/DOX-CCS). The high drug loading
capacity of β-lapachone/DOX-CCS results from the strong
π−π stacking interactions between the benzene rings in the
carrier and drugs. The nanosystem with high loading capacity
Figure 1. Schematic illustrations of the cascade amplification release
process of β-lapachone/DOX-CCS in the tumor cells.
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of β-lapachone 21.6% and DOX 20.7% was chosen to assess its
physicochemical properties in vitro. The morphology and size
of the prepared β-lapachone/DOX-CCS were characterized
using dynamic light scattering (DLS) and transmission
electron microscopy (TEM). As shown in Figure 2a,b, DLS
and TEM reveal that the constructed β-lapachone/DOX-CCS
are spherical ones with a size around 140 nm.
To verify our hypothesis about the cross-linking design, the
nanosystem stability and drug leakage were assessed. When β-
lapachone/DOX-CCS was incubated in phosphate buffered
saline (PBS) with 10% FBS for 24 h, the size change of the
crosslinked β-lapachone/DOX-CCS was much smaller than
that of the noncrosslinked β-lapachone/DOX-NCS, showing
that the crosslinked β-lapachone/DOX-CCS is very stable,
even in the lower concentration 1 mg/mL (Figure 2c).
Furthermore, the leakage of DOX from β-lapachone/DOX-
NCS and β-lapachone/DOX-CCS was compared through
sealing in dialysis bags after exposing to PBS with 10% FBS
(Figure 2d). β-lapachone/DOX-NCS exhibits more leakage of
DOX (18.9%) compared to β-lapachone/DOX-CCS (5.4%)
within 2 h, which provides evidence that the crosslinked
structure would minimize the premature drug leakage and lay
solid foundation for in vivo precise drug release.
To explore the drug release process, β-lapachone/DOX-
CCS was exposed to different redox conditions. PBS solutions
with 2 mM glutathione or 1 μM H2O2 were used to mimic the
physiological environments of the tumor cell. PBS solutions
with 100 μM H2O2 were used to mimic high ROS level
environments after β-lapachone was catalyzed by NQO1. After
24 h incubation, 55 and 32% DOX were released in PBS
solutions with 2 mM glutathione or 1 μM H2O2. However, in
PBS solution with 100 μM H2O2, the DOX release
dramatically increased to 75% (Figure S3, Supporting
Information). These results demonstrate that the nanosystem
could release a portion of DOX/β-lapachone in the presence of
internal stimulants, and DOX/β-lapachone release increases as
H2O2 concentration increases due to the breaking of the
diselenide bond.
3.2. Intracellular Drug Release, Distribution, in Vitro
ROS Assessments, and Synergy Study. Confocal laser
scanning microscopy (CLSM) was applied to observe the
subcellular drug release, distribution, and ROS generation in
NQO1-overexpressing HepG2 cells (Figure 3). Because DOX
acts with DNA and topoisomerase II in the nucleus, DOX
Figure 2. Characterization of β-lapachone/DOX-CCS. (a) Size distribution of β-lapachone/DOX-CCS by DLS. (b) Morphology of β-lapachone/
DOX-CCS by TEM. (c) Size stability of β-lapachone/DOX-CCS at 37 °C in PBS with 10% FBS for 24 h (n = 3). (d) In vitro drug leakage from β-
lapachone/DOX-CCS (n = 3).
Figure 3. Intracellular DOX distribution and in vitro ROS generation
after treatment. CLSM images of HepG2 cells incubated with β-
lapachone/DOX-CCS at 37 °C for 4 h. [DOX concentration 10 mg/
L, the proportion between DOX and β-lapachone in β-lapachone/
DOX-CCS 0.5:5, 1:5, 2.5:5, and 5:5 (w/w)]. Nuclei were stained with
Hoechst 33342 (blue), and ROS was stained with the DCFH-DA kit
(green). The scale bar is 40 μm.
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located in the nucleus after the release is crucial to induce
apoptosis. As shown in Figure 3, DOX-CCS exhibits low
nuclear fluorescence at 4 h. By contrast, all β-lapachone/DOX-
CCS groups have a high nuclear fluorescence, indicating more
DOX release in the tumor cells. The reason is that β-lapachone
could induce ROS generation through NQO1, and ROS
consequently breaks Se−Se bond and release the loaded DOX.
More importantly, with the increase of β-lapachone amounts in
β-lapachone/DOX-CCS, the green fluorescence intensity of
ROS gradually increases and the nuclear distribution of DOX
increases accordingly until the nuclei is completely occupied
(β-lapachone/DOX = 5:5). Average ROS fluorescence in the
cells was quantitatively evaluated by flow cytometry (Figure
4b) and calculated from the CLSM images (Figure S4a,
Supporting Information). The difference between different β-
lapachone amounts in terms of the DOX fluorescence from β-
lapachone/DOX-CCS within the nucleus indicates that β-
lapachone generates abundant exogenous-stimulant ROS via
NQO1 catalysis and plays a crucial role in the drug release.
These results confirm our previous hypothesis about the design
of this nanosystem.
To manifest the effect of drug release triggered by ROS via
NQO1 catalysis, the NQO1 competitive inhibitor dicoumarol
was subsequently introduced for the retrospective method.
Average ROS fluorescence in the cells and DOX fluorescence
in the cell nuclei were calculated from the CLSM images
(Figure S4, Supporting Information). The nuclear fluorescence
of DOX from β-lapachone/DOX-CCS increases progressively
with decreasing amounts of dicoumarol (60, 40, 0 μM)
(Figures 4a, S4d, Supporting Information), which further
confirms that abundant exogenous-stimulant ROS via NQO1
catalysis is important to the cascade drug release.
We investigated the efficiency of β-lapachone-induced ROS
generation in the HepG2 cells. Cells treated with free DOX
(9.58 mg/L), β-lapachone (10 mg/L), or β-lapachone/DOX-
CCS (β-lapachone 10 mg/L and DOX 9.58 mg/L) were
analyzed by a flow cytometer (Figure 4b). β-Lapachone and β-
lapachone/DOX-CCS significantly enhances ROS concen-
tration as the incubation time prolongs. Nevertheless, DOX
barely elevates the intracellular ROS concentration. At 4 h,
ROS fluorescence increases by ∼30 times, and β-lapachone/
DOX-CCS produces a similar amount of ROS as free β-
lapachone, suggesting a high intracellular ROS level.
The combination index (CI) of β-lapachone and DOX was
calculated by Chou−Talalay method (Table S2). CI values
were <1, thus suggesting the synergistic effect of β-lapachone
and DOX.
3.3. In Vivo Pharmacokinetic Study, Biodistribution,
and Intratumoral Release. The in vivo pharmacokinetics of
β-lapachone/DOX-CCS has been conducted. As shown in
Figure S5, after 24 h, 9.4% of β-lapachone/DOX-CCS was in
the plasma compared with 0.3% of free DOX and 5.7% β-
lapachone/DOX-NCS. β-Lapachone/DOX-CCS displayed
longer blood circulation time.
To explore the tumor-targeting of the nanosystem, in vivo
distribution of β-lapachone/DOX-CCS in HepG2-xenografted
mice was systematically studied after injection of β-lapachone/
DOX-CCS at a dose of 10 mg kg−1 for obtaining a clear
imaging effect within a safe limit. The in vivo imaging of mice
was conducted at 8, 12, and 24 h postinjection by the
PerkinElmer IVIS Lumina III Imaging System. As shown in
Figure 5a, more DOX fluorescence of β-lapachone/DOX-CCS
is observed to locate on the tumor tissue at 8 h compared with
free DOX and β-lapachone/DOX-NCS (Figure S6, Supporting
Figure 4. Intracellular DOX distribution and ROS assessments in
vitro. (a) CLSM images of HepG2 cells incubated with β-lapachone/
DOX-CCS and different concentrations of dicoumarol at 37 °C for 4
h (DOX concentration 10 mg/L, dicoumarol concentration 0, 40, 60
μM). (b) Flow cytometry analysis of ROS in HepG2 cells treated with
DOX, β-lapachone, or β-lapachone/DOX-CCS (DOX concentration
9.58 mg/L, β-lapachone concentration 10 mg/L). The scale bar is 40
μm.
Figure 5. In vivo drug accumulation. (a) In vivo optical fluorescence
imaging of mice-bearing HepG2-induced tumor with β-lapachone/
DOX-CCS for 8, 12, and 24 h postinjection (10 mg/kg of DOX). (b)
CLSM images of the HepG2-induced tumor cryosections at 24 h
postinjection of β-lapachone/DOX-CCS. The scale bar is 10 μm.
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Information). Moreover, β-lapachone/DOX-CCS performs
lasting fluorescence at the tumor 24 h, suggesting the long
circulation and excellent tumor-targeting of the nanoparticles
at the tumor site. Quantification of DOX distribution in the
tumors was also conducted by the tissue distribution method
(Figure S7, Supporting Information). DOX in the tumor tissue
reaches as high as 16.7% of the injected dose, which is even
higher than that in the reticuloendothelial system such as liver
and spleen responsible for the clearance of exogenous
nanoparticles and kidney for excretion. The result demon-
strates that the crosslinked nanoparticles could greatly improve
the in vivo tumor-targeting property through preventing
premature drug leakage, which offers opportunity for loaded
drug to accumulate in the tumor tissue.
To clearly observe the intratumoral release and distribution
of DOX in the tumor cell, a portion of tumors were collected at
24 h and CLSM imaging displayed a precise location of DOX
(Figure 5b). Average DOX fluorescence in the cell nuclei was
calculated from the CLSM images (Figure S8, Supporting
Information). The images show that DOX signals of the β-
lapachone/DOX-CCS group in the cell nuclei are remarkably
stronger than that of DOX-CCS group. This result reveals that
β-lapachone could greatly increase the release efficacy and
delivery to the nuclei of tumor cells of DOX from β-
lapachone/DOX-CCS in the tumor cells.
3.4. Antitumor Efficacy. The above results demonstrate
that the enzyme-catalytic self-triggered release of the drug from
the nanosystem is meaningful for tumor therapy at the cellular
level. To show the potential of β-lapachone/DOX-CCS in
vivo, the antitumor efficacy of β-lapachone/DOX-CCS was
assessed in HepG2-xenografted nude mice. Mice-bearing
tumors of 80 mm3 were divided into six groups for the
treatment administered. As shown in Figure 6a,c, the inhibition
rate of tumor growth (IRT) for β-lapachone/DOX-CCS is
92.49%, which is obviously higher than the 47.05% of free
DOX, 67.42% of DOX-CCS, 77.29% of dicoumarol/β-
lapachone/DOX-CCS, and 83.57% of β-lapachone/DOX-
NCS. β-lapachone/DOX-CCS shows higher efficacy on
inhibiting the tumor growth compared with β-lapachone/
DOX-NCS, which verifies that the crosslinked nanoparticles
could improve the in vivo tumor-targeting property. Compared
with DOX-CCS and dicoumarol/β-lapachone/DOX-CCS, β-
lapachone/DOX-CCS shows better efficacy in inhibiting the
tumor growth, which further suggests that sufficient drug
release, efficient drug delivery to the nuclei of tumor cells, and
the synergy of DOX and ROS on tumor suppression are well
fulfilled by β-lapachone/DOX-CCS. Therefore, β-lapachone
and cross-linking could significantly influence characteristics of
the nanosystem and their biological fate in vivo.
To further evaluate the therapeutic efficacy, the excised
tumors were processed for hematoxylin and eosin (H&E)
(Figure 6e). The treatment of β-lapachone/DOX-CCS results
in the highest level of cell apoptosis in the tumor tissue, which
is superior to that of free DOX, DOX-CCS, and β-lapachone/
Figure 6. In vivo antitumor effect. (a) Tumor inhibition curves, (b) body weight change, (c) tumor weight, (d) survival rates, and (e) histological
observation of nude mice bearing HepG2-induced tumors administrated with PBS, free DOX, DOX-CCS, β-lapachone/DOX-NCS, dicoumarol/β-
lapachone/DOX-CCS, and β-lapachone/DOX-CCS (DOX dosage: 5 mg/kg body weight). Data were presented as mean ± standard deviation by
t-test, *p < 0.05, **p < 0.01. The scale bar is 50 μm.
ACS Applied Materials & Interfaces Research Article
DOI: 10.1021/acsami.9b15460
ACS Appl. Mater. Interfaces 2019, 11, 43581−43587
43585
DOX-NCS groups. In groups treated with free DOX,
cardiomyocyte nuclear lysis and glomerular pyknosis were
observed in the heart and kidney (Figure S9). In contrast, β-
lapachone/DOX-CCS resulted in no obvious damage,
suggesting that β-lapachone/DOX-CCS could reduce drug
toxicity.
The survival rate of mice treated with different formulas was
also investigated (Figure 6d). Mice treated with β-lapachone/
DOX-CCS survive over 50 d. Mice treated with PBS, free
DOX, DOX-CCS, and β-lapachone/DOX-NCS do not survive
over 15, 25, 33, and 36 d, respectively. Moreover, the average
body weights of all groups at the end point changed by <15.0%
while about 25.0% weight loss is observed in the free DOX
group (Figure 6b), suggesting negligible side effects of β-
lapachone/DOX-CCS. The safety of β-lapachone/DOX-CCS
might be related to the NQO1 enzyme besides cross-linking.
The low expression of the NQO1 enzyme in the normal cells
results in the lower release of DOX from β-lapachone/DOX-
CCS.
Overall, the synergistic functions of β-lapachone/DOX-CCS,
including precise drug delivery to the nuclei of tumor cells,
oxidative cytotoxicity of ROS, and combined chemotherapy of
DOX and β-lapachone, were demonstrated to improve tumor
inhibition efficacy with reduced adverse effects. Based on the
safety and efficiency of β-lapachone/DOX-CCS, it might serve
as a new direction and lead us to further research for clinical
cancer therapy.
4. CONCLUSIONS
In summary, a core crosslinked nanosystem (β-lapachone/
DOX-CCS), which could self-trigger release of a loaded drug
via enzyme catalysis, has been successfully constructed by the
encapsulation of β-lapachone. The research results reveal that
the crosslinked β-lapachone/DOX-CCS is able to achieve
efficient drug delivery to the nuclei of tumor cells and improve
tumor inhibition efficacy with reduced adverse effects.
Therefore, this research might provide new possibilities in
developing effective yet green cancer therapy paradigms.
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